Chronic Myeloproliferative Neoplasms at CIOC 2027

Chronic myeloproliferative neoplasms (MPNs) are a group of blood cancers characterized by the overproduction of mature blood cells in the bone marrow. This excessive production leads to an increased risk of blood clots, bleeding, and a potential transformation to acute leukemia. Recent research in cancer biology has shed light on the molecular mechanisms driving MPNs, uncovering mutations in genes such as JAK2, CALR, and MPL, which play crucial roles in regulating blood cell production. Targeted therapies, including JAK inhibitors like ruxolitinib, have revolutionized the treatment landscape, offering improved symptom control and potentially altering the disease course. Moreover, emerging immunotherapies and combination treatment approaches hold promise for enhancing patient outcomes and providing a deeper understanding of MPN biology, paving the way for more effective and personalized treatment strategies in the future.